PerkinElmer Introduces Wizard2 Automatic Gamma Counter With Advanced Ease-Of-Use Features
WALTHAM, Mass. – PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced the launch of the new WIZARD2™ Automated Gamma Counter. This next generation gamma counter features a user-friendly interface system with a package of technology advancements for academic, nuclear medicine and pharmaceutical researchers who conduct radiometric immuno assays (RIA), chromium release studies and positron emission tomography (PET) research. The WIZARD® Gamma Counter, a widely known, market leading gamma counter used for radiometric detection in clinical and academic research labs around the world, has been re-engineered to feature Windows® XP software, touch-screen operation, easy networking capability and USB ports for simple data transfer.
“In response to evolving customer needs, we have re-engineered the gamma workhorse, which has always been an integral part of the laboratory environment,” said Dr. Richard Eglen, President, Molecular Medicine, PerkinElmer Life and Analytical Sciences. “We're starting 2008 with a new enhanced product that addresses the demand for a robust and efficient system, yet still offers superior counting performance with all types of samples.”
The technological advances in the new models improve its user-interface and laboratory integration with key features such as:
- A touch screen now directs work flow, replacing a manual keyboard system
- An enhanced user interface delivers easier and more efficient operation for today's multi-user environment
- Enhanced security options support 21 CFR Part 11 compatibility
- Built-in PC with LAN and USB connections facilitate data transfer
While there are many new features and benefits, the WIZARD2
™ counter retains the core design components which have made this instrument an industry leader:
- A well-hole detector that enables accurate measurements of the widest range of samples
- Lead shielding around the conveyor delivers reliably low background and improved detection
- A sophisticated robotic sample handling system to meet the challenges of the most advanced applications
The WIZARD2
™ Automatic Gamma Counter is available in two models:
- The 2470 model, designed for basic research and routine counting applications such as RIA and chromium release studies, comes with 1, 2, 5 or 10 detectors (each with 550-sample capacity), and 5 and 10 detectors (each with 1,000- sample capacity)
- The 2480 model, which offers multilabel counting efficiencies for more sophisticated research applications such as PET (with 1,000- and 270-sample capacity)
Leveraging its market leader position and demonstrating its commitment to the radiometric detection sector, PerkinElmer has also launched a new family of Tri-Carb® liquid scintillation analyzers (LSAs). These essential laboratory instruments, used for many applications that require use of radioisotope tracers, support industries from homeland security to nuclear power, and biofuels to pharmaceuticals. A major step forward in automated sample tracking, the new family of Tri-Carb® LSAs features a barcode reader system, an industry first in liquid scintillation analyzers.
For more information about the WIZARD2™ new product launch, visit www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer Inc.'s Life and Analytical Sciences business unit provides fully integrated, innovative solutions, leveraging deep scientific expertise and dedication to fulfilling customer needs to help scientists advance the pace and precision of their research and testing. It is a leading provider of diagnostic and detection instruments, reagents, software and services for advanced cellular science research and drug discovery, genetic screening, medical imaging, environmental, quality assurance and the health sciences industries.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
For further information regarding PerkinElmer, please contact: Media Contact: Dara Cothran Euro RSCG Worldwide PR (212) 367-6814 dara.cothran@eurorscg.com